Products for Research Use Only
RegisterLogin

Enzalutamide

CAT: 0804-HY-70002-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-70002-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator[1][2].
CAS Number
915087-33-1
Product Name Alternative
MDV3100
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
Androgen Receptor; Autophagy
Type
Reference compound
Related Pathways
Autophagy; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Enzalutamide.html
Purity
99.97
Solubility
DMSO : ≥ 50 mg/mL
Smiles
S=C(N(C(C1(C)C)=O)C2=CC=C(C#N)C(C(F)(F)F)=C2)N1C3=CC(F)=C(C(NC)=O)C=C3
Molecular Formula
C21H16F4N4O2S
Molecular Weight
464.44
Precautions
H315, H319, H335
References & Citations
[1]Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 2009, 324 (5928), 787-790.|[2]Scher HI, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 2010, 375 (9724), 1437-1446.|[3]Guerrero J, et al. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013 Sep;73 (12) :1291-305.|[4]Kim TH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015 Nov;38 (11) :2076-82.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
FC65076-01Enzalutamide
A3003-SMDV3100 (Enzalutamide)

Popular Products